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Background: Nonsteroidal anti-inflammatory drugs (NSAIDs) have been associated with improved survival in some cancers, but
evidence for ovarian cancer is limited.
Methods: Pooling individual-level data from 12 Ovarian Cancer Association Consortium studies, we evaluated the association
between self-reported, pre-diagnosis use of common analgesics and overall/progression-free/disease-specific survival among
7694 women with invasive epithelial ovarian cancer (4273 deaths).
Results: Regular analgesic use (at least once per week) was not associated with overall survival (pooled hazard ratios, pHRs (95%
confidence intervals): aspirin 0.96 (0.88–1.04); non-aspirin NSAIDs 0.97 (0.89–1.05); acetaminophen 1.01 (0.93–1.10)), nor with
progression-free/disease-specific survival. There was however a survival advantage for users of any NSAIDs in studies clearly
defining non-use as less than once per week (pHR¼ 0.89 (0.82–0.98)).
Conclusions: Although this study did not show a clear association between analgesic use and ovarian cancer survival, further
investigation with clearer definitions of use and information about post-diagnosis use is warranted.
Over 238 000 women are diagnosed with ovarian cancer annually
(International Agency for Research on Cancer, 2014) and 5-year
survival is poor at B45% (Howlader et al, 2015). Identifying
modifiable factors that could improve survival is therefore
important. One possible factor is the use of analgesics such as
nonsteroidal anti-inflammatory drugs (NSAIDs). Nonsteroidal
anti-inflammatory drugs, including aspirin and non-aspirin
NSAIDs (NA-NSAIDs), inhibit the pro-inflammatory enzyme
cyclooxygenase (COX). COX-2 is over-expressed in many cancers
including ovarian (Maccio and Madeddu, 2012), and COX-
inhibition can reduce angiogenesis and trigger apoptosis (Xin
et al, 2007). While improved survival among NSAID users has
been reported for breast (Huang et al, 2015), prostate (Liu et al,
2014), and colorectal (Ye et al, 2014) cancers, two previous
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observational studies of ovarian cancer found no evidence that pre-
diagnosis aspirin, NA-NSAID, or acetaminophen use was asso-
ciated with survival (Minlikeeva et al, 2015; Nagle et al, 2015).
However, both studies were underpowered to detect the likely
modest effects. One trial reported no short-term (median follow-
up 34 months) survival advantage among women with advanced
ovarian cancer when a NA-NSAID was added to standard
chemotherapy, but did not examine long-term outcomes
(Reyners et al, 2012). Interestingly, a preliminary report (published
as a conference abstract) has suggested that NSAID use post-
diagnosis may be associated with improved survival (Poole et al,
2016). We used data from a large international consortium to
examine the association between pre-diagnosis use of common
analgesics and survival after a diagnosis of ovarian cancer. We
hypothesised that NSAID users would experience a survival benefit
compared to non-users.
MATERIALS AND METHODS
Study population. We pooled data from 12 case–control studies,
which included 7694 women with invasive epithelial ovarian
tumours, aged o85 years at diagnosis (Supplementary Table 1).
Cancers of unknown behaviour (n¼ 93 high grade; n¼ 25 low
grade) were assumed to be invasive (Trabert et al, 2014). Most
women (59%) had serous cancers; 5%, 15%, and 8% had mucinous,
endometrioid, and clear cell cancers, respectively. Most cancers
(63%) had distant spread.
Exposure, outcome, and covariates. Studies provided data on
self-reported pre-diagnosis analgesic use (Supplementary Table 2;
harmonisation described previously (Trabert et al, 2014)). Two
studies (UCI/UKO) did not report NA-NSAIDs data, so were only
included in ‘aspirin’ and ‘any NSAIDs’ (aspirin plus non-aspirin)
analyses. Regular use was defined as at least once per week vs less
often. Frequency, dose, and duration information was available for
seven, three, and nine studies, respectively (Table 1). Studies
provided data on vital status and time from diagnosis to death or
end of follow-up. Disease recurrence/progression (from 3 studies)
and cause of death (two studies) was known for 28% and 12% of
women, respectively. Ethnicity, smoking status, education, body
mass index (BMI), tumour stage, and residual disease was known
for 99.8%, 89%, 87%, 92%, 99%, and 24% of women, respectively.
Statistical analysis. Using Cox proportional hazards regression,
we obtained hazard ratios (HRs) and 95% confidence intervals
(CIs) for the association between analgesic use and overall survival
(OS) in each study. Potential confounders were selected a priori.
We did not adjust for treatment type because treatment cannot
influence pre-diagnosis analgesic use (as treatment occurs later)
and these data were only available for 25% of the cohort. Main
models were adjusted for age, education, and ethnicity. Survival
time was left-truncated at recruitment to minimise potential bias
from eligible women dying before they could be enroled. Following
proportional hazards assumption checking (inspecting covariate
associations with survival over time), we re-ran models including
covariate*time interactions where these interactions were statisti-
cally significant (two studies). As the resulting estimates were
virtually unchanged, final models did not include these interac-
tions. Site-specific HRs for OS were combined using random-
effects meta-analysis. I2 and P-values for heterogeneity (from chi-
square tests) were inspected to assess inter-study heterogeneity.
Associations between analgesic use and progression-free (PFS) and
disease-specific survival (DSS) were estimated from single models,
stratified by study, to maximise power. In the same manner we
Table 1. The association between regular pre-diagnosis use of common analgesic medications and overall survival following a
diagnosis of invasive ovarian cancer
Aspirin Non-aspirin NSAIDs Any NSAIDs Acetaminophen
Exposure categorisation n pHRa 95% CI I2 n pHRa 95% CI I2 n pHRa 95% CI I2 n pHRa 95% CI I2
Regular useb
No 6190 Ref 5196 Ref 4891 Ref 5908 Ref
Yes 1286 0.96 0.88–1.04 5.5 1570 0.97 0.89–1.05 0.0 2563 0.94 0.86–1.03 32.6 1264 1.01 0.93–1.10 0.0
Frequency (7 studies)c
No regular use 4268 Ref 3993 Ref 3297 Ref 4335 Ref
o30 days per month 234 0.92 0.72–1.18 31.0 498 0.93 0.79–1.09 15.2 572 0.92 0.81–1.06 0.0 532 1.05 0.85–1.30 56.6d
Daily 593 1.01 0.90–1.14 0.0 768 0.99 0.89–1.10 0.0 1226 0.98 0.89–1.07 2.4 419 0.99 0.86–1.13 0.0
Daily dose (3 studies)e
No regular use 1330 Ref 1244 Ref 899 Ref 1484 Ref
Low 125 0.90 0.58–1.39 51.0 253 0.98 0.81–1.18 0.0 299 0.95 0.79–1.13 0.0 65 0.90 0.63–1.27 0.0
High 205 0.92 0.69–1.22 37.2 230 1.10 0.91–1.33 0.0 396 0.92 0.69–1.24 64.2 289 1.09 0.89–1.34 18.5
Duration (9 studies)f
No regular use 3919 Ref 3523 Ref 2889 Ref 4201 Ref
o60 months 426 0.96 0.82–1.13 22.1 483 0.99 0.87–1.13 0.0 689 0.94 0.80–1.11 40.9 253 1.04 0.87–1.24 0.0
60þ months 559 1.01 0.89–1.14 0.0 519 0.90 0.78–1.04 0.0 930 0.98 0.86–1.13 29.8 460 1.00 0.83–1.21 34.4
Abbreviations: CI¼ confidence interval; NSAID¼nonsteroidal anti-inflammatory drug; pHR¼pooled hazard ratio.
aAdjusted for age (in years), ethnicity (if o95% of participants were of the same ethnicity) (White/Hispanic/Black/Asian/Other), and education (Less than high-school/Completed high-school
including some college/College graduate/Education status unknown).
b‘Regular’ use defined as at least once per week (depending on the question used by each study to collect information on medication use); includes all 12 studies for aspirin, 10 studies for non-
aspirin NSAIDs (excluding UCI/UKO, which did not report these data), 12 studies for any NSAIDs (aspirin or non-aspirin), and 11 studies (excluding UKO) for acetaminophen.
cFrequency analyses were conducted in 7 studies with available data (AUS, DOV, HAW, HOP, MAL, NCO, and USC). Frequency of daily use of any NSAID may be slightly underestimated (while
less than daily use may be overestimated), because if aspirin and non-aspirin NSAIDs were each takeno7 days per week, this is categorised as less than daily use of any NSAID although it is
possible that at least one type of NSAID was taken 7 days per week (this cannot be determined from the data available).
dStatistically significant heterogeneity in the pHR across studies.
eLow/High defined as o/Z 100mg/day for aspirin, and o/Z500mg/day for non-aspirin NSAIDs and acetaminophen; includes 3 studies with available data (HAW, HOP, and NCO).
fDuration analyses were conducted in 9 studies with available data (CON, DOV, HAW, HOP, MAL, NEC, NJO, UCI, and USC) for aspirin and acetaminophen, and in 8 studies (excluding UCI) for
non-aspirin NSAIDs and any NSAIDs.
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conducted analyses stratified by characteristics likely to modify the
association (age, BMI, and disease stage).
This analysis and each contributing study received approval
from the appropriate institutional review board/ethics committee.
All participants provided written informed consent.
RESULTS
Population characteristics. Mean age at diagnosis was 58 years,
88% of women were non-Hispanic white, and 27% were tertiary-
educated. Of the 7694 women, 17%, 23%, and 18% had regularly
used aspirin, NA-NSAIDs, and acetaminophen, respectively
(Supplementary Table 1). Median follow-up (using reverse
Kaplan-Meier (Schemper and Smith, 1996)) was 8.0 years. Over
half the women (n¼ 4273, 56%) died and 5-year survival was 55%
(Supplementary Table 1), yielding 90% power to detect a
HR¼ 0.90 for NSAID users. Among studies with progression/
cause-of-death information, 73% of women experienced progres-
sion and 95% of deaths were from ovarian cancer.
Primary results. Regular use of analgesics was not associated with
OS (pHRs (95% CI): aspirin 0.96 (0.88–1.04); NA-NSAIDs 0.97
(0.89–1.05); any NSAIDs 0.94 (0.86–1.03); acetaminophen 1.01
(0.93–1.10)), nor were frequency, dose, or duration of use (Table 1;
Figure 1). There was no significant inter-study heterogeneity
(Figure 1). Additional adjustment for tumour stage and grade,
residual disease, BMI and smoking status did not appreciably alter
effect estimates. Cross-classifying frequency by dosage (among five
studies with data) did not demonstrate consistent associations, and
long-term (Z5 years) daily use was not associated with survival.
Truncating follow-up at five years (when most deaths would
be cancer-related) did not affect results. No significant asso-
ciations were observed with PFS (any NSAIDs, HR¼ 0.96; 95%
CI 0.80–1.14) or DSS (HR¼ 0.98; 95% CI 0.82–1.17). There
was no significant variation by tumour histology (Table 2;
P-interaction¼ 0.3–0.7). Excluding the two studies which
had previously examined this association (Minlikeeva et al, 2015;
Nagle et al, 2015) (whose participants comprised 25% of this
analysis), two studies with high survival rates (these studies
recruited a number of prevalent cases), or two studies who asked
only about recent use (past 5 years), did not substantially alter
effect estimates.
To minimise exposure misclassification due to heterogeneous
questions between studies, we repeated analyses restricted to six
studies clearly defining non-use as less than once per week
(Supplementary Table 3). This showed a significant survival
advantage among regular users of any NSAIDs (pHR¼ 0.89; 95%
Study
Study Study
Study
Hazard
ratio (95% CI)
Hazard
ratio (95% CI)
Hazard
ratio (95% CI)
Hazard
ratio (95% CI)
DOV
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DOV
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1.01 (0.81, 1.25)
A B
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1.09 (0.91, 1.30)
0.92 (0.75, 1.11)
0.91 (0.74, 1.11)
0.92 (0.73, 1.15)
0.89 (0.69, 1.14)
1.04 (0.79, 1.38)
0.96 (0.71, 1.31)
0.90 (0.64, 1.26)
0.91 (0.55, 1.50)
1.88 (0.99, 3.57)
1.02 (0.87, 1.20)
1.13 (0.92, 1.38)
0.88 (0.70, 1.11)
1.07 (0.85, 1.35)
1.04 (0.78, 1.38)
1.02 (0.73, 1.44)
0.76 (0.54, 1.08)
1.14 (0.74, 1.76)
0.83 (0.51, 1.35)
1.01 (0.58, 1.76)
2.31 (0.82, 6.46)
1.01 (0.93, 1.10)
0.97 (0.89, 1.05)
0.90 (0.72, 1.12)
0.99 (0.79, 1.23)
1.04 (0.83, 1.30)
1.16 (0.87, 1.53)
0.97 (0.73, 1.29)
0.88 (0.63, 1.24)
0.79 (0.56, 1.12)
0.85 (0.56, 1.28)
0.66 (0.41, 1.06)
0.72 (0.44, 1.17)
1.64 (0.92, 2.94)
0.96 (0.88, 1.04)
0.88 (0.74, 1.04)
1.00 (0.84, 1.20)
1.03 (0.86, 1.24)
0.84 (0.69, 1.02)
0.92 (0.74, 1.14)
1.14 (0.89, 1.45)
0.93 (0.71, 1.22)
0.89 (0.67, 1.17)
0.83 (0.59, 1.18)
0.70 (0.47, 1.04)
1.74 (1.08, 2.80)
0.72 (0.44, 1.15)
0.94 (0.86, 1.03)
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Overall (I-squared = 5.5%, P = 0.391)
Overall (I-squared = 32.6%, P = 0.130) Overall (I-squared = 0.0%, P = 0.571)
Overall (I-squared = 0.0%, P = 0.559)
NOTE: Weights are from random effects analysis
NOTE: Weights are from random effects analysis NOTE: Weights are from random effects analysis
NOTE: Weights are from random effects analysis
Figure 1. The association between regular pre-diagnosis use of common analgesic medications and overall survival following a diagnosis of
invasive ovarian cancer, adjusted for age, ethnicity (ifo95% of participants are of the same ethnicity), and education. (A) Aspirin, (B) non-aspirin
NSAIDs, (C) any NSAIDs, (D) acetaminophen.
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CI 0.82–0.98). When we excluded studies with low exposure
prevalence (o10%), a similar association was seen among the
eight remaining studies (including the six above; any NSAIDs
HR¼ 0.92; 95% CI 0.85–0.99).
In stratified analyses, an inverse association between any NSAID
use and survival was seen among women aged Z60 at diagnosis
(pHR¼ 0.90; 95% CI 0.82–0.99) or with BMI o25 kgm 2 (0.86;
0.77–0.95). A non-significant inverse association was seen among
women with early-stage (localised/regional) tumours (pHR¼ 0.87;
95% CI 0.74–1.04; Supplementary Table 4).
DISCUSSION
Overall, we did not find convincing evidence to support an
association between use of aspirin, NA-NSAIDs, or acetaminophen
prior to diagnosis and ovarian cancer survival. Although most HRs
for aspirin and NA-NSAIDs were o1.0, none was statistically
significant. Our results are consistent with the two previous
observational studies (Minlikeeva et al, 2015; Nagle et al, 2015)
examining pre-diagnosis use of NSAIDs. The relationship did not
vary by histologic subtype.
Questions used to define regular use differed between studies.
When we restricted analyses to a subset of studies clearly defining
non-use as less than once per week, use of any NSAIDs was
associated with significantly improved survival. No notable
characteristics differentiated these studies from others in the
main analyses. This may suggest that exposure misclassification
attenuated our primary results, and that analyses using a more
consistent definition of use might have more power to detect
modest associations with survival. However the results of these post
hoc analyses require validation and should be interpreted with
caution. The apparent lack of association for long-term daily use of
any NSAIDs among the five studies with this information (this
included studies with potential misclassification of non-users)
could reflect the fact that daily aspirin users are more likely to use
a low-dose preparation, which may be insufficient to confer a
survival benefit.
We did not have information on medication use after diagnosis,
which may be a more relevant time-window, especially if women
change their use after diagnosis. A recent meta-analysis of NSAID
use and breast cancer survival found post- but not pre-diagnosis
use was associated with improved survival (Huang et al, 2015), a
pattern also suggested by the preliminary report (conference
abstract) examining post-diagnosis use among a small number
(N¼ 602) of ovarian cancer patients (Poole et al, 2016). Unless
change in use is associated with survival, the likely effect of using
pre-diagnosis data to estimate post-diagnosis use would be random
misclassification, attenuating any real association. We had
insufficient data to stratify by post-diagnosis prognostic factors
such as treatment received, but additional adjustment for stage/
grade of disease (which predict treatment type) and amount
of residual disease after surgery did not appreciably alter our
estimates.
In conclusion, we did not find convincing evidence of an
association between pre-diagnosis analgesic use and ovarian cancer
survival. However, the modest associations in subgroup analyses
suggest we cannot exclude the possibility that NSAID use is
associated with survival (but we could not detect this due to
exposure misclassification and/or a sub-optimal exposure win-
dow). Further investigation with more consistent definitions of
analgesic use/non-use (including by selective/non-selective COX-2
inhibition) and information about post-diagnosis use is warranted.
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